Thrombocytopenia after COVID-19 vaccination

Kragholm, Kristian; Sessa, Maurizio; Mulvad, Thomas; Andersen, Mikkel Porsborg; Collatz-Christensen, Helle; Blomberg, Stig Nikolaj; Lippert, Freddy; Mikkelsen, Søren; Leutscher, Peter; Melgaard, Dorte; Torp‐Pedersen, Christian; Kristensen, Søren Risom; Larsen, Torben Bjerregaard; Søgaard, Peter

doi:10.1016/j.jaut.2021.102712

Cited by 16 publications

(14 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…COVID-19 vaccine–related thrombocytopenia has been observed as an adverse event and described as various conditions, all of them involving autoimmunity. 11 Vaccine-triggered autoimmunity with vaccination has been known for decades, mainly involving epitope mimicry mechanisms. 12 …”

Section: Discussionmentioning

confidence: 99%

Acquired Thrombotic Thrombocytopenic Purpura After BNT162b2 COVID-19 Vaccine: Case Report and Literature Review

Hammami

Lamarque

Aujoulat

et al. 2022

Laboratory Medicine

View full text Add to dashboard Cite

Thrombotic thrombocytopenic purpura (TTP) is a thrombotic microangiopathy that is deadly if not treated promptly. The treatment of choice in patients presenting with TTP is plasma exchanges. However, immunosuppressive therapy and caplacizumab have significantly improved outcomes in TTP. This microangiopathy is classically divided into 2 entities: hereditary and acquired TTP (aTTP), caused by an autoantibody against ADAMTS 13. We present a case study of a patient wth TTP occurring after a second dose of the BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine along with a review of the literature. A 55-year-old patient presented with gastrointestinal symptoms, anemia, and severe thrombocytopenia. The blood film revealed the presence of schistocytes. A diagnosis of aTTP was established because the patient had severe ADAMTS 13 deficiency and autoantibodies against ADAMTS 13 were positive. This episode occurred 10 days after the patient received the COVID-19 vaccine. The patient received plasma exchanges, prednisone, rituximab, and caplacizumab and achieved complete remission. Ten patients with aTTP induced by the COVID-19 vaccine have been reported in the literature. Most of these situations occurred after the second dose of COVID-19 vaccine, and 7 patients were noted to have received the BNT162b2 vaccine. Caplacizumab was used in 6 patients, and complete remission was achieved in 8 patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Acquired Thrombotic Thrombocytopenic Purpura After BNT162b2 COVID-19 Vaccine: Case Report and Literature Review

Hammami

Lamarque

Aujoulat

et al. 2022

Laboratory Medicine

View full text Add to dashboard Cite

show abstract

“…An epidemiological study found that thrombotic episodes were more common among older adults during the first month post-ChAdOx1 vaccine [ 11 ]. Another study found that thrombotic events were more common in females and in patients younger than 45 years [ 13 – 15 ].…”

Section: Discussionmentioning

confidence: 99%

Upper Limb Ischemia Due to Arterial Thrombosis after COVID-19 Vaccination

Alsmady

Al-Qaryouti

Sultan

et al. 2022

Case Reports in Medicine

View full text Add to dashboard Cite

show abstract

“…Apart from the different self-reported cases and/or media reports, recent studies have also reported AEFI with COVID-19 vaccines, including cases of thrombocytopenia and bleeding without thrombosis, as well as cases of thrombosis without thrombocytopenia reported among individuals who received RNA-based COVID-19 vaccines; Pfizer-BioNTech and Moderna, and also vaccine-induced thrombotic-thrombocytopenia (VITT) following the administration of adenovirus-vector based vaccines; Astra-Zeneca, J&J [16][17][18] . To understand the possible mechanisms involved in the development of thrombotic thrombocytopenia among patients who received the AstraZeneca vaccine, some researchers 17,18 recently reported severe and simultaneous blood clots and reduced platelets counts as immune-mediated response characterizing AstraZeneca vaccine-associated thrombotic thrombocytopenia.…”

Section: Presentation Of Concernsmentioning

confidence: 99%

SARS-CoV-2 vaccines–induced thrombotic thrombocytopenia: should we consider immuno-hypersensitivity?

Reuben¹,

Adogo²

2021

Rev. saúde pública

View full text Add to dashboard Cite

The coronavirus disease 2019 (COVID-19) pandemic is significantly causing unprecedented clinical, socioeconomic, and public health challenges globally. The successful global administration of effective, safe and sustainable vaccine(s) is widely believed to be crucial in mitigating as well as preventing COVID-19. However, the rising cases of severe adverse events following immunization (AEFI) with COVID-19 vaccines including thrombosis, thrombocytopenia, and in some instances, death have created serious global concerns and could enormously contribute to vaccine hesitancy. Although the complete underlying pathophysiology and immunopathology of the COVID-19 vaccines related to AEFI, including thrombosis and/or anaphylaxis, are yet to be determined, exploring possible immuno-hypersensitivity could be crucial in the mechanisms associated with these reactions, thereby mitigating their occurrences as well as restoring confidence in vaccine administration for a COVID-19 free world.

show abstract

Thrombocytopenia after COVID-19 vaccination

Cited by 16 publications

References 9 publications

Acquired Thrombotic Thrombocytopenic Purpura After BNT162b2 COVID-19 Vaccine: Case Report and Literature Review

Acquired Thrombotic Thrombocytopenic Purpura After BNT162b2 COVID-19 Vaccine: Case Report and Literature Review

Upper Limb Ischemia Due to Arterial Thrombosis after COVID-19 Vaccination

SARS-CoV-2 vaccines–induced thrombotic thrombocytopenia: should we consider immuno-hypersensitivity?

Contact Info

Product

Resources

About